Company intelligence / Profile preview

EPOPLUS

Hannover, Lower Saxony, Germany

Ownership: Private
Development stage: Other

Overview

EPOPLUS GmbH & Co. KG was a German biotechnology company based in Hannover, founded in 2004 as a subsidiary of Cytonet GmbH & Co. KG. The company focused on discovering and developing novel therapeutic applications for low-dose erythropoietin (EPO). Its research primarily targeted the stimulation of endothelial progenitor cells to promote organ regeneration, improve wound healing, and slow the progression of end-organ damage. EPOPLUS advanced a low-dose Epoetin beta program into a Phase 2 clinical trial for the treatment of diabetic foot ulcers before the company went into liquidation in late 2013.

Therapeutic areas: EndocrinologyCardiovascularDermatologyNephrology
Modalities: Recombinant proteinBiologic
Industry: Biotech

Beyond the preview

Go deeper on EPOPLUS.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EPOPLUS.

Explore the full profile